The introduction of glycoconjugate vaccines into the arsenal of available weapons that can be used to prevent infectious diseases to overcome the limitations of traditional polysaccharide vaccines, is one of the most important achievements of contemporary vaccinology. CD BioGlyco focuses on the development of glycoconjugate vaccines, providing our customers with carrier protein design services and offering a wide range of high-quality carrier proteins.
Currently licensed glycoconjugate vaccines consist of a carbohydrate fraction, which is covalently attached to a protein carrier. The protein component of glycoconjugate vaccines is actively involved in their immunological process, providing T-cell epitopes that transform a T-cell independent polysaccharide vaccine into a more immunogenic T-cell dependent antigenic vaccine. These epitopes are essential for the induction of high-affinity antibodies at all ages, including infants, and for triggering memory responses.
Several carrier proteins are available for licensed glycoconjugate vaccines, such as tetanus toxoid (TT), diphtheria toxoid (DT), Haemophilus protein D (PD), CRM197, and the outer membrane protein complexes of serogroup B meningococcus (OMPC). OMPC has been used in Hib conjugate vaccines and first-generation pneumococcal conjugate vaccines. PD is produced by a recombinant strain ofE. coli and has been introduced as a carrier for most serotypes in polyvalent pneumococcal conjugate vaccines. CRM197 has been widely used as a carrier for licensed Hib, polyvalent meningococcal and pneumococcal vaccines and other developmental vaccines.
Fig.1 Glycoengineering approach to the production of glycoconjugate vaccines. (Kay, 2019)
CD BioGlyco has established multiple strategies to provide design and development services for new protein carriers in addition to providing customers with high purity proteins already used as carriers in licensed glycoconjugate vaccines. Services we provide include but are not limited to:
Addressing two different virulence factors of pathogens by simultaneously administering carbohydrate and protein antigens, could simplify the formulation of multi-component vaccines with carbohydrate and protein virulence factors against a given pathogen.
We combine the multivalent presentation of carbohydrates with the specific physicochemical properties of nano-sized particles to drive an effective immune response.
Combined with extensive expertise and experience in the field of vaccine development, CD BioGlyco is confident to provide global customers with high-quality carrier protein design services to help them improve and develop safe and effective vaccines. Please feel free to contact us or send us an inquiry directly if you need more details.
Reference:
